Dear Physician, If you have questions regarding bacteriophage therapy, our clinic opening schedule, or if you wish to refer a patient -- please contact Dr. Tengiz Chikvashvili at mailbox@phagetherapycenter.com. Targeted Clinical Pathogens Bacteriophages can be effective against the following clinical pathogens that are resistant to antibiotics: Staphylococcus spp.
Enterococcus spp.
Pseudomonas aeruginosa
Proteus mirabilis, Proteus vulgaris
Streptococcus spp.
Escherichia coli
Salmonella spp.
Shigella spp.
Klebsiella spp. Efficacy is a function of sensitivity of the infection to phages. We therefore recommend sending a live bacterial sample, for testing sensitivity, prior to shipping phages to the patient. Importing Bacteriophages for Patient Use The FDA in the United States will, at their discretion, allow individuals to import bacteriophage medications. Please contact us for specific procedures. Recent Clinical Studies A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy
Wright, A., Hawkins, C.H., Anggard, E.E.& Harper, D.R.
UCL Ear Institute and Royal National Throat, Nose and Ear Hospital, Grays Inn Road, London, and Biocontrol Limited, BioCity, Pennyfoot Street, Nottingham, UK
Clin. Otolaryngol. 2009, 34, 349–357 Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
D.D. Rhoads, MT (ASCP), Laboratory Researcher; R.D. Wolcott, MD, Director; M.A. Kuskowski, PhD, Associate Professor, Department of Psychiatry, University of Minnesota, Minneapolis, US; B.M. Wolcott, Research Technician; L.S. Ward, PhD, Director of Research, Glanbia Research and Development Center, Twin Falls, Idaho, US; A. Sulakvelidze, PhD, Chief Scientist, Intralytix, Baltimore, MD
JOURNAL OF WOUND CARE VOL 1 8 , NO 6, JUNE 2009 Scientific Literature Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases
Shigenobu Matsuzaki, Mohammad Rashel, Jumpei Uchiyama, Shingo Sakurai, Takako Ujihara, Masayuki Kuroda, Masahiko Ikeuchi, Toshikazu Tani, Mikiya Fujieda, Hiroshi Wakiguchi, Shosuke Imai
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2005 MINIREVIEW Bacteriophage Therapy
ALEXANDER SULAKVELIDZE, ZEMPHIRA ALAVIDZE AND J. GLENN MORRIS, JR
Division of Molecular Epidemiology, Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201,1 and Eliava Institute of Bacteriophage, Microbiology, and Virology, Georgian Academy of Sciences, Tbilisi, Georgia 3800602
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 649–659 The prospect for bacteriophage therapy in Western Medicine
Carl R. Merril, Dean Scholl, Sankar L. Adhya
Nature Reviews Drug Discovery Volume 2, June 2003 Old dogma, new tricks -- 21st Century phage therapy
Karl Thiel
Nature Biotechnology Volume 22, Number 1 January 2004
|
